Introduction to the Lawsuit Against Pacira Biosciences
Pomerantz LLP has recently announced that a class action lawsuit has been initiated against Pacira Biosciences, Inc. (NASDAQ: PCRX). Investors who have experienced losses are urged to pay attention to this significant development. The underlying issues revolve around allegations of securities fraud and unreasonable business practices associated with the company.
Details of the Class Action
This class action lawsuit raises questions about the conduct of both Pacira and some of its executives or directors. Investors who purchased or acquired Pacira securities during the specified period should consider asking to be appointed as Lead Plaintiff. The deadline to make such a request is approaching quickly.
Implications of Recent Events on Pacira's Stock
In a recent announcement by Pacira, a significant setback occurred regarding the company's Exparel non-opioid pain treatment. The U.S. District Court handling a patent infringement case declared Pacira's '495 patent invalid. This ruling was based on claims of obviousness and anticipation related to the patent.
As a result of this announcement, Pacira's stock price plummeted by $10.66 per share, marking a staggering decrease of 47.67%. The closing price saw a drastic fall to $11.70 per share on the day of the announcement, which has left many investors concerned.
About Pomerantz LLP
Pomerantz LLP is a prestigious law firm with a long-standing reputation for handling complex securities litigation, corporate accountability, and antitrust class actions. Established over 85 years ago by the renowned Abraham L. Pomerantz, the firm has made substantial strides in the realm of securities class actions. Throughout its rich history, Pomerantz has consistently defended the rights of investors affected by corporate wrongdoing.
Today, Pomerantz continues to champion the rights of those harmed by securities fraud and breaches of fiduciary duty, successfully recovering significant damages for its clients in many instances.
Contact Information for Inquiries
Investors looking to gather more information about the class action or seeking legal representation should consider reaching out to Danielle Peyton from Pomerantz LLP. She is available to assist potential class members in understanding their rights and options in the face of this unfolding situation.
For inquiries, Danielle can be reached at 646-581-9980 or through email. It's advisable for investors to provide essential information such as their mailing address and the number of shares they own during their communications.
Frequently Asked Questions
What is the class action lawsuit against Pacira Biosciences about?
The lawsuit is about alleged securities fraud and unlawful business practices by Pacira and its executives.
How has Pacira's stock performed recently?
Pacira's stock saw a dramatic drop of 47.67% following a court ruling invalidating a key patent for its medication.
Who can join the class action?
Investors who purchased Pacira securities during the specified class period are eligible to join.
What should I do if I want to participate in the lawsuit?
You should contact Pomerantz LLP to seek Lead Plaintiff status and gather details regarding your involvement.
Who are Pomerantz LLP?
Pomerantz LLP is a leading law firm specializing in securities class actions and corporate law, known for its historic victories in advocating for investors.
